Our results from AML and T-NHL were mostly negative for ROR1 protein levels via IHC, so a more restrictive v1-specific anti-ROR1 Ab will not change the IHC prevalence data presented here for these two indications. This evidence concerns the gene ROR1 and acute myeloid leukemia.